Sequence Bio is a biotechnology company based in Newfoundland and Labrador, Canada, dedicated to revolutionizing drug discovery by identifying the true genetic signals of disease. Leveraging the unique genetic makeup of the Newfoundland population, characterized by the founder effect, Sequence Bio combines multi-omic data with comprehensive health records to enhance the understanding, treatment, and prevention of diseases. This approach aims to address the high failure rate of drug candidates, with approximately 90% failing during development, by providing more accurate and efficient drug target identification.
Key Features and Functionality:
- Founder Population Multi-omics: Utilizes the unique genetic characteristics of Newfoundland's founder population to efficiently identify low-frequency, high-impact genetic variants associated with diseases.
- Comprehensive Health Records: Integrates extensive health records to achieve consistent phenotypic stratification, uncovering new links between genetic variants and disease manifestations.
- Integrated Systems Biology Platform: Combines systems biology with data-driven computational methods to accurately identify disease signals, accelerating the drug discovery process.
- Customizable Discovery Cohorts: Collaborates with pharmaceutical and biotech companies to create tailored discovery cohorts for both common and rare disease indications.
- Accelerated Research and Development: Aims to shorten R&D timelines by providing more precise drug targets, thereby reducing costs and expediting the development of new therapeutics.
Primary Value and Problem Solved:
Sequence Bio addresses the critical challenge in the pharmaceutical industry of high drug development failure rates by offering a more precise and efficient method for drug target identification. By harnessing the unique genetic data of Newfoundland's population and integrating it with comprehensive health records, Sequence Bio enhances the understanding of disease mechanisms. This approach leads to the development of better, safer medicines, ultimately improving health outcomes and delivering life-changing treatments to patients in need more rapidly.
